Zombie Virus in Your DNA? NIH's Cancer Vaccine Invention Awaits License
Published Date: 2/20/2026
Notice
Summary
The National Cancer Institute is offering a new cancer-fighting invention for licensing. This invention uses a special protein from an ancient virus in our DNA to create vaccines that help the immune system attack certain cancers without harming healthy cells. Researchers and companies interested in developing this promising treatment can now partner up to bring it to patients faster.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NCI Offering ERVMER34-1 License
The National Cancer Institute (NCI) is offering a government-owned invention (NIH Reference Number E-159-2019-0) for licensing and seeks research co-development partners to translate peptide-based therapeutic cancer vaccines derived from ERVMER34-1. The technology is in pre-clinical (in vivo) development and the notice invites researchers and companies to pursue licensing or collaboration.
Preclinical Results Suggest Broad Tumor Targeting
NCI researchers report that the ERVMER34-1 vaccine platform shows tumor-selective expression across about 62% of carcinomas and achieved approximately 89% tumor clearance in established large tumors in mouse models when combined with checkpoint inhibitors. These results are pre-clinical (in vivo) and support development of peptide- or vector-based therapeutic cancer vaccines and adoptive T cell therapies.
Patent Filings Protect Commercial Rights Globally
Patent applications for this invention are pending in multiple jurisdictions, including the US (US application 17/793,753 filed 2022-07-19), Europe, Canada, Australia, and Hong Kong, indicating intellectual property protection is being pursued for commercial development. Interested licensees should note the international pending patent status when evaluating licensing and commercialization strategies.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11892 — Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute)
The National Cancer Institute wants your thoughts on a new way to track and locate cancer research samples through their Specimen Resource Locator. This affects researchers and labs who use these samples, aiming to make finding and sharing easier without adding extra costs or delays. You’ve got 60 days to share your feedback and help shape this helpful tool!
2026-11390 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-11367 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting science projects. If you’re involved in cell biology, heart disease, mental health, or cancer research, these reviews could impact your funding timeline and opportunities.
2026-11357 — National Library of Medicine; Notice of Partially Closed Meeting
The National Library of Medicine’s Board of Regents will hold a virtual meeting on July 16, 2026, with some parts open to the public and others closed to protect private info and trade secrets. This meeting affects researchers and grant applicants, as grant reviews will happen behind closed doors. Anyone can watch the open sessions online and send comments up to 15 days before the meeting—no registration needed!
2026-11018 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late June and early July 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10813 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Previous / Next Documents
Previous: 2026-03337 — Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases
The National Institutes of Health is fixing a small but important detail in their patent license for a new treatment that uses special immune cells to fight autoimmune diseases. This change clarifies how the treatment’s genetic material is delivered, either by non-viral nanoparticles or viral systems. If you want to comment or apply for a license, you’ve got until March 9, 2026, so don’t miss out!
Next: 2026-03339 — Steel Concrete Reinforcing Bar From Mexico: Amended Final Results of Antidumping Duty Administrative Review; 2022-2023
The U.S. Department of Commerce fixed some small mistakes in the review of steel concrete reinforcing bars (rebar) from Mexico for the 2022-2023 period. This change affects Mexican companies like Deacero and impacts the final duties they owe when selling rebar in the U.S. The updated results took effect on February 20, 2026, making sure the trade rules are fair and accurate.